Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)

ROCKET AF Investigators

doi:10.1161/CIRCULATIONAHA.113.005008

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)

ROCKET AF Investigators

Research output: Contribution to journal › Article › peer-review

353 Citations (Scopus)

Abstract

Background-Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger patients. Methods and Results-There were 6229 patients (44%) aged ≥75 years with atrial fibrillation and ≥2 stroke risk factors randomized to warfarin (target international normalized ratio=2.0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance

Original language	English
Pages (from-to)	138-146
Journal	Circulation
Volume	130
Issue number	2
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.113.005008
Publication status	Published - Jul 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.113.005008

Fingerprint

Dive into the research topics of 'Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)'. Together they form a unique fingerprint.

Cite this

ROCKET AF Investigators (2014). Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation, 130(2), 138-146. https://doi.org/10.1161/CIRCULATIONAHA.113.005008

ROCKET AF Investigators. / Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). In: Circulation. 2014 ; Vol. 130, No. 2. pp. 138-146.

@article{8c6a0c588e1d468ea9eeffff299c8ba4,

title = "Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)",

abstract = "Background-Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger patients. Methods and Results-There were 6229 patients (44%) aged ≥75 years with atrial fibrillation and ≥2 stroke risk factors randomized to warfarin (target international normalized ratio=2.0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance",

author = "{ROCKET AF Investigators} and J.L. Halperin and Hankey, {Graeme J.} and D.M. Wojdyla and J.P. Piccini and Y. Lokhnygina and M.R. Patel and G.U. Breithardt and D.E. Singer and R.C. Becker and W. Hacke and J.F. Paolini and C.C. Nessel and K.W. Mahaffey and R.M. Califf and K.A.A. Fox",

year = "2014",

month = jul,

doi = "10.1161/CIRCULATIONAHA.113.005008",

language = "English",

volume = "130",

pages = "138--146",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

ROCKET AF Investigators 2014, 'Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)', Circulation, vol. 130, no. 2, pp. 138-146. https://doi.org/10.1161/CIRCULATIONAHA.113.005008

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). / ROCKET AF Investigators.
In: Circulation, Vol. 130, No. 2, 07.2014, p. 138-146.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)

AU - ROCKET AF Investigators

AU - Halperin, J.L.

AU - Hankey, Graeme J.

AU - Wojdyla, D.M.

AU - Piccini, J.P.

AU - Lokhnygina, Y.

AU - Patel, M.R.

AU - Breithardt, G.U.

AU - Singer, D.E.

AU - Becker, R.C.

AU - Hacke, W.

AU - Paolini, J.F.

AU - Nessel, C.C.

AU - Mahaffey, K.W.

AU - Califf, R.M.

AU - Fox, K.A.A.

PY - 2014/7

Y1 - 2014/7

N2 - Background-Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger patients. Methods and Results-There were 6229 patients (44%) aged ≥75 years with atrial fibrillation and ≥2 stroke risk factors randomized to warfarin (target international normalized ratio=2.0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance

AB - Background-Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger patients. Methods and Results-There were 6229 patients (44%) aged ≥75 years with atrial fibrillation and ≥2 stroke risk factors randomized to warfarin (target international normalized ratio=2.0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance

U2 - 10.1161/CIRCULATIONAHA.113.005008

DO - 10.1161/CIRCULATIONAHA.113.005008

M3 - Article

C2 - 24895454

SN - 0009-7322

VL - 130

SP - 138

EP - 146

JO - Circulation

JF - Circulation

IS - 2

ER -

ROCKET AF Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014 Jul;130(2):138-146. doi: 10.1161/CIRCULATIONAHA.113.005008